Merus to Participate in a Fireside Chat at the Jefferies Healthcare Conference 2023
31 Maggio 2023 - 2:00PM
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company
developing innovative, full-length multispecific antibodies
(Biclonics® and Triclonics®), today announced that Bill Lundberg,
M.D., President, Chief Executive Officer of Merus, will participate
in a fireside chat at the Jefferies Healthcare Conference 2023 on
Wednesday, June 7, 2023 at 11:30 a.m. ET.
The webcast of the presentation will be contemporaneously
available on the Investors page of the Company's website. The
archived presentation will also be available there for a limited
time after the event.
About MerusMerus is a
clinical-stage oncology company developing innovative full-length
human bispecific and trispecific antibody therapeutics,
referred to as Multiclonics®. Multiclonics® are manufactured
using industry standard processes and have been observed in
preclinical and clinical studies to have several of the same
features of conventional human monoclonal antibodies, such as long
half-life and low immunogenicity. For additional information,
please visit Merus’ website and Twitter.
Multiclonics®, Biclonics® and Triclonics® are
registered trademarks of Merus N.V.
Investor and Media Inquiries:
Sherri Spear
Merus N.V.
VP Investor Relations and Corporate Communications
617-821-3246
s.spear@merus.nl
Kathleen Farren
Merus N.V.
IR/Corp Comms
617-230-4165
k.farren@merus.nl
Grafico Azioni Merus NV (NASDAQ:MRUS)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Merus NV (NASDAQ:MRUS)
Storico
Da Mag 2023 a Mag 2024